The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Oryzon Genomics‘ iadademstat, an investigational oral therapy for people with acute myeloid leukemia (AML). “Receiving Orphan Drug Designation for iadademstat in AML is an important recognition of the role that new drugs with new mechanisms of action may bring to this patient community, where we do not yet have any potentially curative medicines besides stem cell transplant,” Torsten Hoffmann, PhD, Oryzon’s global…

You must be logged in to read/download the full post.